Observational trial to assess the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients

Trial Profile

Observational trial to assess the efficacy of nivolumab (Nivo) as 2+ line treatment and quality of life (QoL) in advanced refractory non-small cell lung cancer (NSCLC) patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2017 Interim results (n=172) presented at the 18th World Conference on Lung Cancer
    • 12 Sep 2017 Interim results (n=172) presented at the 42nd European Society for Medical Oncology Congress.
    • 12 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top